secwatch.observer — SEC 8-K summary
======================================

Issuer:     PUMA BIOTECHNOLOGY, INC. (PBYI)
CIK:        0001401667
Form:       8-K
Filed at:   2021-11-04T23:59:59+00:00
Accession:  0001437749-21-025291
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Puma Biotechnology Q3 net loss widens to $44.7M; product revenue falls 12%
--------------------------------------------------------------------------

- Q3 product revenue $43.4M, down from $49.3M YoY; COVID-19 impact and inventory reduction of ~$3.5M.
- GAAP net loss $44.7M ($1.09/share) vs $31.5M ($0.79/share) in Q3 2020; non-GAAP adj. loss $40.4M.
- Cash, cash equivalents, and marketable securities $87.5M at Sep 30; operating cash flow $10.5M positive.
- Nine-month 2021 total revenue $197.8M included $50M upfront from Pierre Fabre for Greater China rights.
- Milestones: SUMMIT trial data, FDA Type C meeting for accelerated approval in HER2-mutated breast cancer, regulatory decisions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401667/000143774921025291/0001437749-21-025291-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401667/000143774921025291/pbyi20211103_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-21-025291

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer